Probably because of differences in degrees of tumor stage among the treated patients and differences in applied therapies prior the PSMA-RLT, this considerable finding is slightly superior to results of previous studies that have demonstrated response rates to PSMA-RLT of about 60–70% in the treated mCRPC patients [4, 6, 14–16]. This evidence concerns the gene FOLH1 and neoplasm.